Francis Bichat

KRN951, a Highly Potent Inhibitor of Vascular Endothelial Growth Factor Receptor Tyrosine Kinases, Has Antitumor Activities and Affects Functional Vascular Properties

Kazuhide Nakamura, Eri Taguchi, Atsushi Yamamoto et al. · Cancer Research · 2006 · 204 citations · Full text

Tumor penetration of gefitinib (Iressa), an epidermal growth factor receptor tyrosine kinase inhibitor

David McKillop, E. A. Partridge, John Kemp et al. · Molecular Cancer Therapeutics · 2005 · 125 citations

Discovery of a 9-mer Cationic Peptide (LTX-315) as a Potential First in Class Oncolytic Peptide

Bengt Erik Haug, Ketil André Camilio, Liv Tone Eliassen et al. · Journal of Medicinal Chemistry · 2016 · 109 citations · Full text

Class Oncolytic Peptide, Potential First, Peptide Engineering +25

Unraveling the Interaction between Carboxylesterase 1c and the Antibody–Drug Conjugate SYD985: Improved Translational PK/PD by Using Ces1c Knockout Mice

Ruud Ubink, Eef H.C. Dirksen, Myrthe Rouwette et al. · Molecular Cancer Therapeutics · 2018 · 48 citations · Full text

Cytoskeleton alteration in MCF7R cells, a multidrug resistant human breast cancer cell line.

Francis Bichat, Roger Mouawad, Guadalupe Solis-Recendez et al. · PubMed · 1998 · 28 citations

Breast Oncology, Vimentin Expression, Immunology +18